I thought… I thought JK did an excellent job of explaining why enrolment will increase in clinical practice and once the SOC versus under the strict Trial criteria
Which also helps to explain the underestimated EBITDA calculations and the true addressable market (300,000 to 400,000) or 2 to 3 times more than the number of patients assumed (140,000) in the EBITDA calculations.
That plus the guided and comparable EBITDA multiples mentioned during the presentation , mean that a new SP valuation/ calculation will soon be in order !
Also good to see that JK is committed to seeing this through and sees it the culmination of his life's work in Sepsis and hemoperfusion.
Excited to see what transpires in the next 12-24 months !!
Holding and strategically still accumulating based on explosive potential.
MM